Assignee
RIGSHOSPITALET
DK14 patents
Top patents by PatentIndex Score
US10111969B2Oct 30, 2018
uPAR targeting peptide for use in peroperative optical imaging of invasive cancer
RIGSHOSPITALET7 citations81
US9573984B2Feb 21, 2017
Chimeric inhibitor molecules of complement activation
RIGSHOSPITALET6 citations80
US9381243B2Jul 5, 2016
Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
RIGSHOSPITALET5 citations79
US9433589B2Sep 6, 2016
Injectable pharmaceutical compositions comprising adrenaline and citric acid
RIGSHOSPITALET12 citations77
US7108983B1Sep 19, 2006
Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker
RIGSHOSPITALET11 citations74
US7807379B2Oct 5, 2010
Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker
RIGSHOSPITALET3 citations54
US12521454B2Jan 13, 2026
68Ga- and 64Cu-NODAGA-E[c(RGDyK)]2 for use as PET tracers in the imaging of angiogenesis in humans
RIGSHOSPITALET0 citations51
US11819552B2Nov 21, 2023
Antibody-drug conjugates targeting uPARAP
RIGSHOSPITALET0 citations51
US10940213B2Mar 9, 2021
Antibody-drug conjugates targeting uPARAP
RIGSHOSPITALET1 citations51
US11203622B2Dec 21, 2021
MASP isoforms as inhibitors of complement activation
RIGSHOSPITALET0 citations48
US10294286B2May 21, 2019
Chimeric inhibitor molecules of complement activation
RIGSHOSPITALET0 citations48
US12226495B2Feb 18, 2025
18F-labeled novel tetrazines imaging probes for pretargeting in PET imaging
RIGSHOSPITALET0 citations45
US7374886B2May 20, 2008
Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
RIGSHOSPITALET1 citations42
US12433916B2Oct 7, 2025
Cell bank of high concentration adipose-derived stem cell composition and related methods
RIGSHOSPITALET0 citations30